Toggle Main Menu Toggle Search

Open Access padlockePrints

Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma

Lookup NU author(s): Steven White

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 The AuthorsBackground: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates. Methods: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023. Results: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%. Conclusion: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.


Publication metadata

Author(s): Smits J, Chau S, James S, Korenblik R, Tschogl M, Arntz P, Bednarsch J, Abreu de Carvalho L, Detry O, Erdmann J, Gruenberger T, Hermie L, Neumann U, Sandstrom P, Sutcliffe R, Denys A, Melloul E, Dewulf M, van der Leij C, Chevallier P, Wigmore S, Newhook T, Vauthey J-N, Memeo R, Dasari BV, Braunwarth E, Aldrighetti L, van Baardewijk L, Barbier L, Binkert C, Bjornsson B, Andorra EC, Arslan B, Baclija I, Bemelmans M, Bent C, de Boer MT, Bokkers RPH, de Boo D, Breen D, Breitenstein S, Bruners P, Cappelli A, Carling U, Casellas i Robert M, Chan B, De Cobelli F, Cha C, Choi J, Crawford M, Croagh D, van Dam R, van Dam R, Deprez F, Diaz-Nieto R, Dili A, Erdmann JI, Font JC, Davis R, Delle M, Fernando R, Fouraschen S, Fretland AA, Fundora Y, Gelabert A, Gerard L, Gobardhan P, Gomez F, Guiliante F, Grochola LF, Grunhagen D, Gimenez JG, Hagendoorn J, Heil J, Heise D, Herrero E, Hess G, Hilal MA, Hoffmann M, Iezzi R, Imani F, Inmutto N, James S, Garcia Borobia FJ, Jovine E, Kalil J, Kingham P, Clarunis OK, Kleeff J, Lopez-Ben S, Macdonald A, Meijerink M, Lapisatepun W, Leclercq W, Lindsay R, Lucidi V, Madoff DC, Martel G, Mehrzad H, Menon K, Metrakos P, Modi S, Moelker A, Montanari N, Moragues JS, Lopez JN, Nguyen J, Peddu P, Primrose J, Damink SO, Qu X, Raptis DA, Ratti F, Ryan S, Ridouani F, Borel Rinkes IHM, Rogan C, Ronellenfitsch U, Serenari M, Salik A, Sallemi C, Martin ES, Sarria L, Schadde E, Serrablo A, Settmacher U, Smits M, Snitzbauer A, Soonawalla Z, Sparrelid E, Spuentrup E, Stavrou G, Tancredi I, Tasse JC, Teichgraber U, Udupa V, Valenti DA, Vass D, Vogl T, Wang X, White S, De Wispelaere J-F, Wohlgemuth W, YU D, Zijlstra I

Publication type: Article

Publication status: Published

Journal: HPB

Year: 2024

Pages: epub ahead of print

Online publication date: 16/07/2024

Acceptance date: 11/07/2024

Date deposited: 30/09/2024

ISSN (print): 1365-182X

ISSN (electronic): 1477-2574

Publisher: Elsevier B.V.

URL: https://doi.org/10.1016/j.hpb.2024.07.407

DOI: 10.1016/j.hpb.2024.07.407


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
12501
Dutch Cancer Society

Share